Opuviz Eylea

Bio & Pharma Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea

A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical...

Bio & Pharma Samsung Bioepis gets EC's approval for Opuviz

South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...

Bio & Pharma Celltrion applies for approval in Europe for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...

Bio & Pharma Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...